# A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer

> **NCT07661173** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Anhui Provincial Cancer Hospital** · enrollment: 154 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Firmonertinib
- **DRUG:** Firmonertinib/pemetrexed/Carboplatin
- **DRUG:** Firmonertinib/pemetrexed/Carboplatin/Bevacizumab

## Key facts

- **NCT ID:** NCT07661173
- **Lead sponsor:** Anhui Provincial Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-06
- **Primary completion:** 2029-03-06
- **Final completion:** 2031-05-06
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2026-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07661173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07661173, "A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07661173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*